Magnesium in schizophrenia.

Abstract

Many psychopathological symptoms, including schizophrenia, can be associated with magnesium metabolism disturbances. In the literature, contradictory data exist regarding magnesium levels in patients with this disorder. However, this situation might be caused by determination of extracellular concentration of magnesium; although, this is mainly an intracellular ion. There are no data concerning determination of the ionized fraction of magnesium in patients with schizophrenia, while the ionized fraction represents 67% of the total pool of magnesium in healthy people. Also, the mechanism of magnesium action-the effect of magnesium ions on NMDA and GABA receptors-has not yet been fully investigated. There are preliminary studies aimed at increasing the effectiveness of schizophrenia pharmacotherapy via magnesium supplementation. Multidirectional activity of magnesium can significantly increase its therapeutic effect in psychiatry. This observation is confirmed by recent studies conducted by various research teams. However, further studies on the role of magnesium supplementation in patients with schizophrenia are needed.

• Authors: Michal Ordak, Joanna Matras, Elzbieta Muszynska, Tadeusz Nasierowski, Magdalena Bujalska-Zadrozny
• Journal: Pharmacological reports : PR (Pharmacol Rep) Vol. 69 Issue 5 Pg. 929-934 (Oct 2017) ISSN: 2299-5684 [Electronic] Switzerland
• PMID: 28651118 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Chemical References

• Antipsychotic Agents
• Magnesium

Topics

• Antipsychotic Agents (administration & dosage, therapeutic use)
• Humans
• Magnesium (administration & dosage, pharmacology)
• Schizophrenia (drug therapy, metabolism, pathology)